Synairgen, the respiratory drug discovery and development company which originated from research at the University of Southampton, has released positive results from its clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalized COVID-19 patients.   “We are all delighted with the trial results announced today, which showed that SNG001 greatly reduced the number of hospitalized COVID-19 patients who progressed from ‘requiring oxygen’ to ‘requiring ven...